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Development and Pathology of Pulmonary Hypertension
Rubin M. Tuder, MD,* Steven H. Abman, MD,† Thomas Braun, MD, PHD,‡
Frédérique Capron, MD, PHD,§ Troy Stevens, PHD, Patricia A. Thistlethwaite, MD, PHD,¶
Sheila G. Haworth, MD#
Denver, Colorado; Bad Neuheim, Germany; Paris, France; Mobile, Alabama; San Diego, California;
and London, United Kingdom
The Development and Pathology working group was charged with reviewing the present knowledge, gaps in un-
derstanding, and areas for further studies in a broad range of themes. These themes in pulmonary vascular biol-
ogy and pathobiology involved: 1) pulmonary vascular development; 2) pulmonary vascular disease accompany-
ing fetal development and perinatal life; 3) properties of pulmonary vascular endothelial cells; 4) role of bone
marrow cells in pulmonary vascular disease; 5) insights into pulmonary thromboembolic disease; 6) role of pa-
thology in the assessment of pulmonary vascular disease; and 7) considerations of tissue banking for research
in pulmonary hypertension. These important goals provide a blueprint for future research that may significantly
impact our present and future understanding of pulmonary hypertension. (J Am Coll Cardiol 2009;54:S3–9)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.009i
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uecent work has shown that in the normal lung, the
re-acinar arteries and post-acinar veins form by vasculo-
enesis from the splanchnopleural mesoderm of the lung
ud (1). Serial reconstruction of human embryos indicates
hat the pulmonary arteries and veins arise by the sustained
ddition of newly formed coalescing endothelial tubes de-
ived by vasculogenesis from the mesenchyme of the lung
round the airway terminal buds. This occurs while pre-
cinar airway branching continues. Angiogenesis appears to
redominate after 15 to 17 weeks’ gestation during intra-
cinar formation. Many of the signaling molecules ex-
ressed in the early human embryo, such as endothelial cell
itric oxide synthase (eNOS), vascular endothelial growth
actor and its receptors, angiopoietins, the endothelial-
pecific receptor TIE-2, transforming growth factor
TGF)-, hypoxia inducible factors 1 and 1, and the
one morphogenetic proteins (BMPs) and their receptors,
ave been studied in vitro and in transgenic models, but
ow these and other molecules orchestrate developmental
rocesses in life is still unclear. Several important ques-
ions remain to be addressed. These include: 1) the
lucidation of the signaling processes responsible for the
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Manuscript received February 6, 2009; accepted April 15, 2009.nduction of the pulmonary capillary networks forming
round each epithelial bud, the mechanisms regulating
he coalescence of the endothelial tubes in the mesen-
hyme, their fusion with the growing pulmonary artery, and
he organization of the randomly formed endothelial cells
e.g., lining up alongside the developing airways, arteries on
ne side and veins on the other); 2) the precise role of
mbryonic and fetal lung signaling molecules and how they
elate to one another; 3) the role of oxygen-sensing mech-
nisms, which have been described in the postnatal lung, in
tero, and at birth; 4) understanding the crosstalk between
pithelial and vascular cells in this complex orchestrated
evelopmental process; 5) clarifying the interplay between
entral pulmonary arteries and the proximal intrapulmonary
rteries during development (e.g., whether they develop
imultaneously or independently); 6) determining the extent
o which extrapulmonary cells are incorporated into the
eveloping pulmonary vasculature; 7) establishing the basis
f the heterogeneity of all the structural components of the
essel wall; 8) determining the potential for vascular cell
aintenance of genetic memory that can influence cell
henotype and the response to injury in postnatal life; and
) ascertaining whether the primordial human lung has a
unctional circulation throughout its development, as has
een shown in the chick embryo.
The developing pulmonary arteries and veins become
nvested by smooth muscle cells from different anatomic
ources. The smooth muscle cells show orderly acquisi-
ion of specific cytoskeletal components, but we need to
nderstand the expression patterns of other features, such
s K channels, which would allow the identification of
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phenotypes. Furthermore, it re-
mains unclear whether such
phenotypic features would per-
tain to the specific origin of the
smooth muscle cells, either
from the lung bud mesenchyme
or from a specific extrapulmo-
nary source. We strongly be-
lieve that pulmonary vascular
development should be consid-
ered a critical determinant of
the propensity to develop pul-
monary vascular disease in later
life.
Mechanisms Regulating
Crosstalk Between
Airway and Vasculature
During Development and
the Pathogenesis of
Neonatal Lung Diseases
In addition to being among the
primary causes of pulmonary hy-
pertension (PH), pulmonary vas-
cular diseases are strongly associ-
ated with abnormalities of lung
development. Normal lung vas-
cular development is critical for
successful adaptation and survival
at birth and in postnatal life.
Studies of mechanisms that reg-
ulate development of the pulmo-
nary circulation have been rela-
ively limited and largely descriptive in nature. However,
ecent observations have challenged older notions that the
evelopment of the blood vessels in the lung passively
ollows that of the airways. The mechanisms by which the
ung successfully achieves normal gas exchange require the
rowth and maintenance of an intricate system of airways
nd vessels, including the establishment of a thin yet vast
lood–gas interface, which is continuously modulated under
oth physiologic and pathologic conditions (2,3).
Increasing evidence suggests that lung blood vessels actively
romote normal alveolar growth during development and
ontribute to the maintenance of alveolar structures throughout
ostnatal life (4–7). Disruption of angiogenesis during lung
evelopment can impair alveolarization, and preservation of
ascular growth and endothelial survival may promote lung
rowth and structure of the distal airspace. Understanding how
lveoli and the underlying capillary network develop and how
hese mechanisms are disrupted in disease states is critical for
eveloping efficient therapies for lung diseases characterized by
Abbreviations
and Acronyms
BMP  bone
morphogenetic protein
BMPR  bone
morphogenetic protein
receptor
BPD  bronchopulmonary
dysplasia
CDH  congenital
diaphragmatic hernia
CTEPH  chronic
thromboembolic pulmonary
hypertension
eNOS  endothelial nitric
oxide synthase
EPC  endothelial
progenitor cell
IPAH  idiopathic
pulmonary arterial
hypertension
PAH  pulmonary arterial
hypertension
PCH  pulmonary capillary
hemangiomatosis
PH  pulmonary
hypertension
PPHN  persistent
pulmonary hypertension of
the newborn
PVOD  pulmonary veno-
occlusive disease
TGF  transforming growth
factor
WHO  World Health
Organizationmpaired alveolar structure. CRecent advances in the field of vascular biology have
rovided novel experimental tools to probe how pulmonary
lood vessels are assembled during early embryonic and fetal
evelopment. These tools may provide important new
nformation regarding pediatric lung diseases associated
ith PH. Developmental abnormalities of the pulmonary
irculation contribute to the pathophysiology of such dis-
ases as persistent PH of the newborn (PPHN), lung
ypoplasia, congenital diaphragmatic hernia (CDH), con-
enital heart disease, and others. This may be especially
mportant in understanding the pathogenesis of broncho-
ulmonary dysplasia (BPD), which is the chronic lung
isease that follows premature birth. BPD is characterized
y arrested lung growth, which may play a central role in the
nsuing decreased alveolarization and a dysmorphic vascu-
ature (8–10).
Experimental data further suggest a potential therapeutic
ole for modulation of angiogenesis for lung diseases that are
haracterized by arrested alveolar growth, such as BPD. The
pidemiology and risk factors for PPHN, BPD, and CDH
emain to be defined, along with the gene–environment
nteractions underlying their pathobiology and biomarkers
maternal, neonatal) to identify at-risk infants. Clinical
rials are needed to improve therapeutic interventions to
reat PH and enhance distal lung growth and function.
oninvasive methods to assess pulmonary hemodynamics
nd lung vascular growth and structure are also needed.
urthermore, advances in stem cell biology suggest at least
otential roles for endothelial progenitor cells (EPCs) and
esenchymal stem cells in the pathogenesis or treatment of
ung vascular disease, especially in experimental models of
PD (11,12).
Future work aimed at better defining the basic mecha-
isms of lung vascular growth and development will likely
ead to novel therapeutic approaches to diseases associated
ith impaired vascular growth or PH. In addition, there is
clear need to better understand the developmental phys-
ology of the lung circulation, especially regarding perinatal
maternal, placental, fetal, and neonatal) mechanisms that:
) regulate vascular tone and reactivity in utero and matu-
ational changes during normal development; 2) alter vas-
ular tone, reactivity, and function in models of PPHN,
ncluding disruption of growth factors, cytokines, and re-
ated signaling pathways; and 3) disrupt lung vascular
rowth and structure. In addition, further studies are needed
o clarify the normal physiology and pathobiology of
PCs. Naive or transfected EPC strategies may have a
ritical role in the restoration of vascular growth and
unction with impact on maintenance of alveolar struc-
ure. EPCs may serve as potential biomarkers used to
iagnose neonatal pulmonary vascular disease over the
ifetime of an individual.
For the realization of these goals, there is a pressing need
or multicenter interventional studies aimed at the preven-
ion of BPD and the treatment of severe PH in BPD and
DH. These approaches should be spearheaded by inter-
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June 30, 2009:S3–9 Development and Pathologyational working groups of pathologists with special exper-
ise in lung development and PH for the diagnostic review
f cases. Consortia are needed to collect, process, and study
ung tissues in order to enhance clinical research.
ulmonary Endothelial Cell Biology
n Health and Disease
ndothelial cells display remarkable heterogeneity in struc-
ure and function, all along the pulmonary arterial-capillary-
enous axis. This segment-specific heterogeneity can be
llustrated by examining lectin-binding patterns within the
ulmonary circulation (13,14). Extra-alveolar endothelial
ells (artery and vein) interact with the lectins Helix pomatia,
ut not with Griffonia simplicifolia, whereas microvascular
ndothelial cells (capillary) interact with Griffonia simplici-
olia, but not with Helix pomatia. Using lectin binding as
ne approach to guide the study of pulmonary endothelial
ell function, it has become apparent that microvascular
ndothelial cells possess greater adhesion strength, unique
echanosensing properties, different organization of signal-
ng networks (e.g., cAMP, calcium, and oxidants), high
lycolytic flux, and a discrete distribution of organelles,
ompared with pulmonary artery endothelial cells (13,14). It
s interesting that the site-specific functions of pulmonary
rtery and microvascular endothelial cells are retained when
opulations of these cells are studied in culture, providing
he opportunity to dissect mechanisms underlying pheno-
ypic heterogeneity. Recent in vitro studies have revealed
hat endothelial cell populations are enriched with progen-
tor cells, which account for the cells’ growth and angiogen-
c/vasculogenic potential (15). Whereas EPCs comprise
nly 5% to 10% of the pulmonary artery endothelial cell
olony, nearly 50% of microvascular endothelial cells are
ade up of progenitor cells. EPCs may play a key role in
ascular development, maintenance in the post-natal period,
nd repair following injury. However, progenitor cells that
eside within the vascular wall may also play unappreciated
oles in vascular disease.
Idiopathic pulmonary arterial hypertension (IPAH) is a
rominently pre-capillary disease that is characterized by
arge and intermediate-sized pulmonary arteries/arterioles
n which there is intimal hyperplasia with medial and
dventitial hypertrophy and hyperplasia. In advanced stages
f PH, cells originating within the vessel wall (smooth
uscle cells, endothelial cells, and fibroblasts), and poten-
ially cells from the circulation, assemble in a “plexiform”
esion (16–18). Disordered endothelial cell growth has
een documented in patients with IPAH, even in pul-
onary artery endothelial cells that are isolated from the
atients and grown in culture (16). These findings
upport the idea that endothelial cells acquire a pro-
roliferative, apoptotic-resistant phenotype that, in the
ase of the plexiform lesion, contributes to the loss of the
ndothelial cell monolayer (17). bWe have only a rudimentary understanding of how
ndothelia contribute to the vascular pathology in IPAH.
t present, the origin of endothelial cells within the
lexiform lesion is not resolved; it may involve the
articipation of large or small pulmonary artery endothe-
ial cells, with variable contribution of bone marrow
recursors. However, cells within the lesion interact with
riffonia simplicifolia, consistent with a microvascular
henotype. It is not clear whether PH selects for progen-
tor cells within the vessel wall and whether cells con-
ributing to either the intimal or plexiform lesion repre-
ent an overgrowth of EPCs. It is also not clear whether
pigenetic modifications or somatic mutations contribute
o the uncontrolled growth of endothelial cells in IPAH
atients. Indeed, considerable work is needed to address
hese and related concerns regarding fundamental endo-
helial cell biology in IPAH.
In summary, questions that remain to be answered are:
) What are the molecular determinants of an EPC?
) What is the unique cell biology of an EPC? 3) Is there an
ncreased propensity for progenitor cells to cause an endo-
helial lesion? 4) Do hyperproliferative endothelial cells arise
y somatic mutations, epigenetic modifications, or selection
f progenitor cells (e.g., apoptosis resistance)? 5) Where are
he EPCs located in vivo, and which signals activate their
rowth?
ole of Bone Marrow Cells in
ulmonary Vascular Structure and Remodeling
he term “bone marrow-derived cells” characterizes a wide
ariety of cell populations that differ with respect to their
iological characteristics, expression of marker molecules,
nd biological functions. These cells range from macro-
hages to inflammatory cells, EPCs, and fibrocytes.
hereas some of these cell populations may represent
argets for potential treatments (e.g., macrophages, inflam-
atory cells, and fibrocytes), others, such as EPCs, might be
tilized as therapeutic agents. However, the rationale for the
herapeutic use of such cells is unclear, and the evidence for
eneficial effects is still limited. In general, it is accepted that
irculating EPCs and fibrocytes play important roles in
ngiogenesis and vascular remodeling (19,20). It should be
ointed out, however, that the literature is replete with
onflicting data reporting significant differences in the
ontribution of EPCs to neoangiogenesis. Since EPCs were
rst described (21), their identity and relative contribution
o neovasculature formation have remained controversial.
onflicting reports of the extent of the contribution of these
ells to new blood vessel formation can be ascribed to a
imited analysis of the EPC phenotype in each study and a
ack of more definitive methods for distinguishing vessel-
ncorporated bone marrow-derived endothelial cells and
ntimately associated perivascular cells. Yet another source
f variability may result from the specific disease processes
eing investigated (tumor neovascularization, hypoxia-
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Development and Pathology June 30, 2009:S3–9nduced neovascularization, PAH, cardiac ischemia, limb
schemia, and others).
The incorporation of endothelial or smooth muscle cells
rom bone marrow into the growing, adult, or aging lungs
ppears to be negligible (22). Circulating fibrocytes, hybrid
ells expressing myeloid and fibroblast markers, may be
ecruited from the bloodstream to promote tissue remodel-
ng during organ and vascular fibrosis (19,23). These fibro-
ytes may represent a new target to prevent tissue remod-
ling, but their precise role in the pathogenesis of PAH
emains unclear. It will be interesting to determine whether
PCs contribute to this process via integration into the
ndothelium and whether the same process also occurs in
he lung. The finding that TGF-1 induces endothelial
ells to undergo endothelial-to-mesenchymal transforma-
ion, whereas BMP-7 has been found to preserve the
ndothelial phenotype, may offer an interesting opportunity
o intervene in this process.
There is still uncertainty about the therapeutic and
athogenetic impact of bone marrow cells in PH. Thera-
eutic infusion of in vitro cultured and eNOS-transfected
PCs increased survival and reduced right ventricular pres-
ure and hypertrophy in rats with monocrotaline-induced
H (24). In mice, bone marrow injection attenuated
onocrotaline-induced PH but aggravated chronic hypoxic
H (25). An open, placebo-controlled pilot study on the
ffect of autologous EPC infusion in IPAH reported an
mprovement in exercise capacity and hemodynamics (26).
owever, compelling evidence is still lacking that autologous
PC infusion has decisive effects in the development of PH.
ore studies are required to come to definitive conclusions and
o elucidate pathogenetic mechanisms that might explain the
ffects of circulating bone marrow-derived cells.
In summary, there is a need to clarify: 1) whether bone
arrow and mononuclear cells are of potential therapeu-
ic value with respect to pathogenic mechanisms and
linical efficacy; 2) whether improvement of cell-based
herapies will have an impact on clinical outcome;
) whether the extent of the contribution of EPCs from
ifferent organs plays a role in the pathogenesis of PH;
) whether the contribution of different types of EPCs
ffects the pathogenesis of PH; and 5) whether there is
ndeed a relatively low-level contribution of bone marrow-
erived EPCs and potentially of smooth muscle cell precursors
n pulmonary hypertensive vasculopathy, which emphasizes the
equirement for accurate quantitative assessments. All clinical
tudies should be performed using precisely defined precursor
ell populations that have been isolated according to accepted
nd reproducible protocols.
ellular and Molecular Underpinnings
f Large Pulmonary Arteries and
icrocirculation in Thromboembolic Disease
hronic thromboembolic pulmonary hypertension (CTEPH)
s a rare disease that is estimated to result in approximately a.8% of all cases of acute pulmonary embolism (27). Several
echanisms have been postulated to cause CTEPH after an
cute embolic event, including recurrence of embolism in 2.5%
o 7% of adequately treated pulmonary embolic events, in situ
hrombus propagation into branch pulmonary vessels, and
ailure to resolve the initial embolus, leading to large- and
mall-vessel vasculopathy (28). In the proximal pulmonary
rterial tree, unresolved pulmonary emboli cause vascular ob-
truction of the vessel lumen by 2 mechanisms: 1) direct
cclusion of the vessel lumen; and 2) induction of secondary
ndothelial changes of cellular hyperplasia, webbing, and in-
omplete clot remodeling. In a subset of patients with
TEPH, small pulmonary arterioles also manifest a pathologic
rocess similar to that seen in PAH, whereby these vessels
ecome excessively thickened by muscular hypertrophy and
brointimal hyperplasia, leading to eventual occlusion (29,30).
he importance of pulmonary arteriolar/capillary remodeling
n the development of CTEPH is supported by the following
acts: 1) there is lack of correlation between elevated pulmonary
rterial pressure and the degree of angiographic pulmonary
ascular bed obstruction in humans; 2) PH can progress in the
bsence of recurrent venous thromboembolism; and 3) total
ulmonary vascular resistance is still significantly higher in
TEPH patients than in acute pulmonary embolism patients
ith a similar percentage of vascular bed obstruction (31,32).
In addition to physically occluding the vessel lumen,
hrombi act as a physical trap for circulating mitogenic,
nflammatory, and vasoreactive factors, many of which can
nterfere with or alter the function of the adjacent endothe-
ium. Endothelial barrier dysfunction, leading to increased
ndothelial permeability, is evident in response to baro-
rauma, inflammation, acute lung injury, and clot retention
33). Changes in shear stress due to vascular occlusion may
lso influence endothelial cell function and production of
asoreactive and mitogenic factors. Because platelets are a
ource of numerous inflammatory, vasoactive, mitogenic,
nd chemotactic factors (e.g., thromboxane A2, serotonin,
latelet-activating factor, angiopoietin-1), their aggregation
n the thrombus should influence endothelial function. In
ummary, a retained clot in the pulmonary vascular tree is
hought to be an instigator of endothelial permeability,
esulting in access of growth factors, cytokines, mitogens,
nd vasoreactive factors to both pulmonary artery endothe-
ial cells and pulmonary artery smooth muscle cells. There is
lso preliminary evidence that thromboemboli in the prox-
mal pulmonary arterial tree contains EPCs that migrate
nto the vessel wall and contribute to the remodeling process
34).
Although the clinical characteristics of CTEPH have
een well defined, understanding of its cellular and molec-
lar mechanisms is lacking. The prevailing opinion is that
H resulting from chronic thromboembolism is a conse-
uence of unresolved pulmonary emboli with adjacent
ascular remodeling as well as a secondary vasculopathy in
mall pulmonary arterioles and capillaries. Mechanistic par-
llels with other forms of PH (e.g., IPAH) have been
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June 30, 2009:S3–9 Development and Pathologyrawn, particularly in light of similar histopathology in
ome distal arteriolar beds (35). Many questions remain, the
ost fundamental of which deal with elucidation of risk
actors and pathogenesis of CTEPH. Future research
hould answer several questions, including: 1) why most
atients with pulmonary embolism do not develop
TEPH; 2) why some individuals fail to resolve acute
hromboembolic obstruction of the pulmonary vascular tree;
) why some CTEPH patients have postoperative residual
H; and 4) whether patients with unsatisfactory postoper-
tive outcomes have cellular, molecular, and genetic abnor-
alities in the pulmonary vasculature similar to those in
atients with IPAH. Furthermore, investigation is needed
o define the role of: 1) inherited defects in coagulation,
ncomplete/defective fibrinolytic pathways; 2) pulmonary
rtery endothelium contributing to the intimal changes that
ccur adjacent to a thromboembolism in main, lobar, and
egmental pulmonary arteries; 3) infiltrating cell types from
he thromboemboli; cellular proliferation of fibromyocyte,
yocyte, and endothelial subtypes within the vessel wall; 4)
one marrow progenitors as either bystanders or active
emodeling agents; and 5) bone morphogenetic protein
eceptor (BMPR)-1A and angiopoeitin-1/TIE-2 signaling
n CTEPH. From a scientific and diagnostic point of view,
here is need: 1) to develop an animal model for CTEPH;
) to design better diagnostic modalities to distinguish
TEPH from IPAH; and 3) to study signaling pathways
nd patterns of gene expression and understand their
otential clinical significance in the treatment of patients
efore and after pulmonary endarterectomy.
athology of PH: Evian, Venice, and Beyond
he pathologic interpretation of pulmonary vascular remod-
ling in PH has been central in studies related to the disease.
s outlined by Zaiman et al. (36), the importance of
athology in the clinical management or even the diagnosis
f PH has fallen behind the direct assessment of pulmonary
rtery pressures using pulmonary arterial catheterization or
stimation of right ventricular pressures using echocardiog-
aphy. Infrequently, lung biopsies have served as a basis for
he diagnosis of PH. Furthermore, the importance of proper
dentification of the different forms of pulmonary vascular
emodeling, or so-called pulmonary vascular lesions, in
tudies of the pathogenesis of PH and the effects of
otential treatments cannot be underestimated. Key ques-
ions concern the role of pathology of PH in the near future.
hich recommendations regarding pathology of PH will
est serve clinicians and, ultimately, patients? Is there a
lassification that should be added to or substituted for
rior classifications?
To answer these questions, it is useful to review the
ifferent classifications used for the last 50 years. These
riginated from international conferences, that is, the 1973
orld Health Organization (WHO) symposium, the 1998
vian, France, international meeting, and the 2003 inter- national meeting held in Venice, Italy. The 1973 WHO
ymposium stressed the contribution of pulmonary vascular
athology in the classification of the disease, an emphasis
hat was eventually superseded by developments in hemo-
ynamic assessment and novel clinical algorithms. The
vian meeting recommended a descriptive approach, based
n acknowledged limitations in interpreting and correlating
athology with specific causes, severity grades, and out-
omes (37). This descriptive approach emphasized a com-
ination of the classic microanatomic and lesional nomen-
lature with the underlying cellular components that
haracterize the lesion. It therefore followed the recommen-
ation that lesional descriptors, such as eccentric or concen-
ric, plexiform or dilation lesions, be identified based on
heir location in the intimal, medial, and/or adventitial
egions. An attempt to complement this approach with one
ased on the recognition of particular cells involved in the
tructure of a lesion implied that investigation of the
aseline abnormalities of pulmonary vascular cells might
ffer an insight into the underlying diagnosis and potential
herapeutic responses of different forms of PH. This ap-
roach attempted to incorporate the use of immunohisto-
hemical markers and opened the possibility that functional
arkers related to disease pathogenesis might serve as
otential tools for enhancing the importance of pathology in
he diagnosis and prognosis of PH. As these dysfunctions
re segregated by vascular cell types, most prominently
ndothelial (38) or smooth muscle cells, the application of
hese tools is expected to provide a much-needed insertion
f pathology into the clinical workup of patients with PH.
he identification of mutations of receptors in the TGF-
amily, particularly of BMPR-2, further highlights the
verall need for such an approach.
The Venice symposium (39) made several recommenda-
ions, the intent of which was to “provide a more descriptive
pproach to . . . the main vascular changes and the associ-
ted pathological alterations.” The report discussed the
escriptions of intimal, medial, and adventitial thickening.
he intimal lesions were segregated into concentric cellular,
oncentric acellular, and eccentric lesions. Complex vascular
esions were categorized as an individual category of lesions.
hese included plexiform and dilation lesions, arteritis,
cclusive venous thrombotic lesions, and pulmonary micro-
asculopathy (also known as pulmonary alveolar capillary
emangiomatosis). Given the common denominator of
MPR-2 mutations in some forms of pulmonary veno-
cclusive disease and pulmonary microvasculopathy, the
ecommendations leave open a potential continuum be-
ween pre-capillary PH and venous disease associated
ith PH.
In the present discussions, it was agreed that pathology
hould have a primary role in documenting the types and
xtent of vascular lesions and associated morphologic alter-
tions in lung tissue from patients and animals with PH.
his systematic approach should serve to correlate pulmo-
ary vascular pathology with clinical presentation/outcome.
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Development and Pathology June 30, 2009:S3–9systematic approach based a multilevel analysis should be
utlined, primarily at the examination of hematoxylin– and
osin–stained slides, further supported by cell structural
mmunohistochemical markers, and potentially in the fu-
ure, complemented by the detection of pathobiologically
elevant markers. These recommendation are very much in
ine with those made in the Evian meeting (37).
ulmonary Vascular Pathology:
ecommendation on Reporting and
xamination of Pulmonary Venopathy
he proper interpretation of pulmonary vascular remodeling
equires that the pulmonary vessels be correctly identified,
ith determination of topography of the vascular lesions.
rteries have to be named according to their location and
ccompanying airway structure, with approximate estima-
ion of diameter. For example, pulmonary arteries can be
roperly labeled as intralobular arteries if they are seen
ccompanying terminal bronchioles. A similar approach can
e applied to veins, including their location in the lobule
intralobular), or in pre-septal or intraseptal locations. Pul-
onary arterial lesions may involve isolated medial hyper-
rophy, medial hypertrophy and intimal thickening, concen-
ric lamellar, eccentric, concentric nonlaminar, complex
esions with plexiform parts, and arteritis. Plexiform/
omplex lesions are usually similar in the lungs of individual
atients. Plexiform lesions with venous and capillary
hanges may coexist in similar parts of the lung. Vascular
hanges can be segmental.
Coexisting venous-venular changes should be noted. These
nclude several potential occlusive lesions, such as intimal
hickening/obstruction (fibrosis, cells), luminal septa, recanali-
ation, adventitial thickening, muscularization, iron and cal-
ium incrustation, and foreign body reaction. Associated cap-
llary changes may be present with multiplication and
roliferation with variable dilatation. Angioma-like lesions and
rimary capillary angiomatosis may be present. Most if not all
ases have associated variable arterial changes. Other changes
nclude dilated lymphatics, hemosiderin-laden alveolar macro-
hages, and type II cell hyperplasia.
In addition to an extensive literature on the arterial
ndings in PH (40,41), there is increasing awareness of
ompromise of the venous circulation in PAH. Pulmonary
eno-occlusive disease (PVOD) now belongs together with
ulmonary capillary hemangiomatosis (PCH) to the PAH
roup, with predominance of vascular disease at the post-
apillary level of the pulmonary vasculature. There is a
ossible overlap between PVOD and cases of PCH, a
isease classically characterized by an aggressive, patchlike,
apillary angioproliferation, as outlined in a report of 35
ases of PVOD and PCH sharing similar histologic patterns
42). The observed post-capillary lesions involve septal veins
nd pre-septal venules and frequently consist of a loose,
brous remodelling of the intima that may totally occlude
he lumen. The involvement of pre-septal venules should beonsidered as necessary for the histologic diagnosis of
VOD, as fibrous occlusion of large septal veins may be
een in many forms of pulmonary venous hypertension,
ncluding a frequently reported obstruction of large pulmo-
ary veins following catheter ablation for cardiac atrial
brillation (43).
issue Banking for Pulmonary Vascular Research
urrently, there are some initiatives to bank human lung tissue
or pulmonary vascular research. In North America, the Car-
iovascular Medical Research and Educational Fund has set up
multi-institutional effort to collect diseased lung tissue for
esearch in IPAH, under the Pulmonary Hypertension Break-
hrough Initiative (44,45). This network interfaces multiple
ransplant centers with tissue processing sites, genomics, cell
rocessing, and proteomics centers. The process of organiza-
ion and operational infrastructure has proved to be complex
ut, since the network has succeeded in its goals, it provides an
xample that can be followed in the future. Furthermore, it has
ighlighted the complexities of setting up a bank of tissue,
ncluding delicate regulatory issues that have to be methodi-
ally addressed prior to setting up this type of enterprise. At
his time, local or regional tissue banks involving various
nstitutions may be more feasible. However, exchange of
araffin blocks of diseased lungs with PH among centers that
tudy the disease is highly desirable. More importantly, this
ffort may offer a unique opportunity to better define the
atural history of IPAH and potentially to identify early
ascular lesions indicative of the disease.
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